All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Join our
How to sequence BCMA-directed therapies in early relapsed/ refractory multiple myeloma
At the ESH 7th Translational Research Conference:
Multiple Myeloma
with Martin Kaiser, Mohamad Mohty, and Rakesh Popat
Saturday, October 5, 2024 | 09:10-10:10 CEST
Register nowThis independent educational activity is funded by GSK. All content is developed independently by the faculty. The funders are allowed no influence on the content of this activity.
The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma hub is an independent medical education platform, sponsored by Sanofi, Bristol Myers Squibb, GSK and Roche, and supported through a grant from Janssen Biotech, Inc. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
A generic version of lenalidomide capsules has been approved by the FDA for MDS and MM
On October 19, 2021, the U.S. Food and Drug Administration (FDA) approved an abbreviated new drug application for a generic version of lenalidomide capsules, a thalidomide analogue, for oral use in patients with multiple myeloma (MM) and myelodysplastic syndromes (MDS).1 The approval includes 2.5 mg and 20 mg strengths, and a tentative approval for 5 mg, 10 mg, 15 mg, and 25 mg strengths.
Lenalidomide capsules are used for the treatment of adult patients with:
- MM, in combination with multiple regimens for the treatment of newly diagnosed and relapsed/refractory patients.
- MM, as maintenance therapy following autologous hematopoietic stem cell transplantation. Read the National Institute for Health and Care Excellence (NICE) recommendation here.
- Transfusion-dependent anemia due to low- or intermediate-1-risk MDS associated with a deletion 5q abnormality with or without additional cytogenetic abnormalities. Find out more about this on the MDS Hub.
- Chronic lymphocytic leukemia, only for use as part of controlled clinical trials.
You can find the full prescribing, safety information and black box warning here.
- Dr. Reddy's. Dr. Reddy's Laboratories announces approval for lenalidomide capsules from the U.S. Food and Drug Administration (USFDA). https://www.drreddys.com/media/1034160/press-release-lenalidomide-capsules-approval.pdf. Published Oct 19, 2021. Accessed Oct 20, 2021.
Your opinion matters
41 votes - 23 days left ...
Related articles
Newsletter
Subscribe to get the best content related to multiple myeloma delivered to your inbox